ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Criqui, G.
Right arrow Articles by Balmes
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Criqui, G.
Right arrow Articles by Balmes, , JR
Eur Respir J 2000; 15: 856-862
Copyright © ERS Journals Ltd 2000

Clinical Trial

Effects of azithromycin on ozone-induced airway neutrophilia and cytokine release

GI Criqui, C Solomon, BS Welch, RE Ferrando, HA Boushey, and Balmes JR

Exposure of humans to ozone causes increased neutrophils and inflammatory cytokines in airway lining fluid. Recent research shows that macrolide antibiotics may reduce interleukin (IL)-8 production by bronchial epithelial cells and inhibit neutrophil chemotaxis. A double-blind, cross-over study was performed in which 12 healthy subjects underwent two separate 4-h exposures to 0.2 parts per million ozone while exercising intermittently. In the 73.5 h before exposure, subjects were pretreated with either 1,250 mg azithromycin or placebo. Sputum induction conducted 74 h pre- and 18 h post-exposure was used to measure total cells, per cent neutrophils, IL-6, and IL-8. There were significant (p<0.05) pre- to post-exposure increases in total cells, neutrophils, IL-6 and IL-8 in both the azithromycin and placebo arms. However, no significant differences were found between azithromycin and placebo conditions in the post- minus pre-exposure value for these variables. The results suggest that in healthy subjects, in the design used, azithromycin, in usual clinical doses, does not have anti-inflammatory effects on human airways as indicated in the measured variables.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Bosnar, B. Bosnjak, S. Cuzic, B. Hrvacic, N. Marjanovic, I. Glojnaric, O. Culic, M. J. Parnham, and V. E. Haber
Azithromycin and Clarithromycin Inhibit Lipopolysaccharide-Induced Murine Pulmonary Neutrophilia Mainly through Effects on Macrophage-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-1{beta}
J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 104 - 113.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Arjomandi, I. Schmidlin, P. Girling, K. Boylen, R. Ferrando, and J. Balmes
Sputum Induction and Bronchoscopy for Assessment of Ozone-Induced Airway Inflammation in Asthma
Chest, July 1, 2005; 128(1): 416 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
O. Holz, R. Tal-Singer, F. Kanniess, K. J. Simpson, A. Gibson, R. S. J. Vessey, S. Janicki, H. Magnussen, R. A. Jorres, and K. Richter
Validation of the Human Ozone Challenge Model as a Tool for Assessing Anti-Inflammatory Drugs in Early Development
J. Clin. Pharmacol., May 1, 2005; 45(5): 498 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Chinn
Statistics for the European Respiratory Journal
Eur. Respir. J., August 1, 2001; 18(2): 393 - 401.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.